2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Clinical Procedures, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Quality of Care, Diseases, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Immunology, GVHD, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Animal Model
PAPER

2479 Belumosudil in pediatric patients with steroid-refractory chronic graft-versus-host disease

Lipeng Liu, Fang Liu2, Xiaofan Zhu, MD3, Wenyu Yang4
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Introduction: The lack of data in pediatric steroid-refractory (SR) chronic graft-versus-host disease (cGVHD) patients contributes to poor prognosis, especially in young children. Belumosudil has been approved for treating SR-cGVHD in adults, but the use of belumosudil in pediatric patients is still scarce. This study aims to investigate the efficacy and safety of belumosudil in pediatric patients with SR-cGVHD.

Methods: This case series included 49 consecutive pediatric patients with SR-cGVHD who had failed multiple lines of treatment (LOTs) and were enrolled and treated with belumosudil between January 2024 and September 2025. The primary endpoint was the overall response rate (ORR), failure-free survival (FFS), and overall survival (OS). Adverse effects (AEs) during belumosudil administration were documented.

Results: All patients had cGVHD that was refractory or steroid-dependent (requiring additional agents to facilitate steroid taper) to their last systemic LOT, and 83.7% (41/49) had received ≥2 prior LOTs. Moreover, all affected organs were also evaluated; the most common organs involved at baseline were skin (29 patients [59.2%]), liver (23 patients [46.9%]), GI tract (18 patients [36.7%]) and lung (14 patients [28.6%]). No patients had genitourinary involvement at baseline. The median time to response was 6 (range, 2-16) weeks, and the best ORR was 81.6%, including 38.7% of patients who achieved complete response (CR). In 14 patients with lung cGVHD, the ORR was 64.3% (95% CI, 35.1-87.2). The DOR rate at 24 weeks was 74.1% (95% CI, 66.5%-81.7%), indicating that most responders maintained their response through at least 24 weeks of follow-up. The best ORR was also assessed in other affected organs, and organ-specific analyses demonstrated a best ORR of 93.1% in the skin, 90.0% in the mouth, 90.9% in the liver, 87.5% in the eyes, and 94.9% in the gastrointestinal (GI) tract. The best ORR was also assessed in other affected organs, and organ-specific analyses demonstrated an ORR of 93.1% in the skin, 90.0% in the mouth, 90.9% in the liver, 87.5% in the eyes, and 94.9% in the gastrointestinal tract. Organ-specific CR rates were highest in the skin (51.7%), mouth (50.0%), liver (34.8%) and eyes (37.5%), while the lung had a CR rate of 14.3%. The overall FFS was 77.0% (95% CI, 70.1-83.9), and OS was 100%. There were no drug-related discontinuations or deaths when received belumosudil.

Discussion: Belumosudil was effective and well-tolerated in pediatric patients with SR-cGVHD after multiple LOTs, and most included patients reduced the dose or discontinued using corticosteroids and other immunosuppressive regimens to minimize their side effects and cost burden.

Lipeng Liu: No relevant conflicts of interest to declare.